Cryoport Stock Hits Highs; More to Follow

There's a veritable gold rush going on right now in the area of personalized therapies. Companies like Novartis and Gilead (KITE) were among the...

Cryoport Revenue Grows 48% for First Quarter; 62% in Biopharma

Tailwinds' Take: this stock represents the definition of "tailwinds". They have a very large secular move happening underneath them and they are the only...

Roth Recap

I had the extreme pleasure of spending the last three days in Dana Point at the Roth Conference. This is annually The Best Small/Micro...

Cryoport Reports 56% Revenue Growth for Fiscal Year Ended December 31, 2017

IRVINE, Calif., March 6, 2018 /PRNewswire/ -- Cryoport, Inc. (CYRX) (CYRXW) ("Cryoport" or the "Company"), the global leader in temperature-controlled logistics dedicated to the life sciences...

McKesson Specialty Health and Cryoport Collaborate to Bolster Logistics Services to Support Commercialization of...

Tailwinds' Take: Very big news for Cryoport. McKesson is late to the regenerative therapy game and are trying to aggressively play catch-up with Cardinal...

Cryoport To Provide TiGenix With Cutting Edge Cold Chain Logistics for Clinical Trial of...

IRVINE, California, February 5, 2018 - Cryoport, Inc. (NASDAQ: CYRX, CYRXW) (“Company”), the world's leading temperature controlled logistics company dedicated to the life sciences...

Previewing 2018…What to Expect From Our Portfolio

As we enter the new year it is very difficult not to be optimistic...borderline exuberant. The Tailwinds Select Portfolio has been on a tear...

Cryoport…Reimbursement Issues, or Non-Event?

Yesterday an article came out on Bloomberg that discussed the issues with reimbursement on Gilead's latest drug, Yescarta. For those who don't know, Yescarta...

Cryoport’s Shares May Be Taking A Breather, But Its Business Can’t Be Slowed

It's been a while since we wrote about Cryoport. At that time, the shares of CYRX were on an absolute tear and it had...

Cryoport Revenue Up 52%; Driven by BioPharma

Tailwinds' Take: with recent approvals from Kite and Novartis, along with 20 Phase III drug partnerships, Cryoport is poised to have explosive revenue growth...

Cryoport Launches New Website for CryoStork Cryogenic Logistics Solutions for the Reproductive Health Market

IRVINE, Calif., Oct. 26, 2017 /PRNewswire/ -- Cryoport, Inc. (NASDAQ: CYRX, CYRXW) ("Cryoport" or the "Company"), the world's leading cold chain logistics company serving the life...

Cryoport Selected to Support the Potential Commercial Launch of Kite Pharma’s CAR-T Therapy Axicabtagene...

Tailwinds' Take: CYRX holds a commanding position in the delivery of regenerative therapeutics. KITE's drug will be the second approved in this space. Expect...

Cryoport Revenue Up 52% for the Second Quarter of 2017, Driven by Biopharma

Tailwinds' Take: CYRX is in a sweet spot and will be for at least the next couple of years as they will continue to...

Cryoport to Support Launch of Potential Treatment for Relapsed/Refractory Acute Lymphoblastic Leukemia

Tailwinds' Take: This announcement was well anticipated, but great news nonetheless. Revenue guidance of $8-10M per annum from this contract is double trailing 12...

Cryoport Biotech Activity Index “CoBRA Index” increases 30.1% in Q1 2017

IRVINE, Calif., June 19, 2017 /PRNewswire/ -- The Cryoport Biotech Activity Index (the "CoBRA IndexSM") quantifies the activity in the development and clinical trials of...

Cryoport Expands Agreement with Sanaria to Support Grant Awards with U.S. National Institutes of...

Tailwinds' Take: CYRX's competitive strength will result in a number of partner relationships going forward as more trials move towards Phase III and commercialization.  IRVINE,...
video

The Cryoport (CYRX) Investment Thesis

This video details the competitive strength and upcoming catalysts for CYRX.

Cryoport: Delivering Results

I often refer to Silicon Valley as having a printing press for making money. It literally seems to grow on trees not only down...

Cryoport Revenue Grows by 74%, Driven by Biopharma

Tailwinds' Take: 27 new clients and 14 new trials demonstrates the strength of their competitive positioning in the growing biopharma space. The company is...

Cryoport Added to the Tailwinds Select Portfolio

As of this morning, at $2.09 per share, we have added Cryoport (CYRX) to the Tailwinds Select Portfolio. Cryoport is in the business of shipping...